Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Risk Adapted Treatment for Primary AML in Adults, Based on Genetics and Minimal Residual Disease (MRD) in Patients up to the Age of 70 Years.

NCT01723657 is registered in ClinicalTrials.gov with Grupo Cooperativo de Estudio y Tratamiento de las Leucemias Agudas y Mielodisplasias as lead sponsor.

NCT NCT01723657
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01723657 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Risk Adapted Treatment for Primary AML in Adults, Based on Genetics and Minimal Residual Disease (MRD) in Patients up to the Age of 70 Years.
Lead sponsor
Grupo Cooperativo de Estudio y Tratamiento de las Leucemias Agudas y Mielodisplasias
Phase
Phase 2
Overall status
Completed
Start date
October 31, 2003
Completion date
March 31, 2012
Enrollment
862 (actual)
Sites
21

Conditions

As the registry lists them; a condition with its own page is linked.

leukemia, myelocytic, acute